Lisa K Naeger

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients
    Lisa K Naeger
    Division of Antiviral Products, Center for New Drug Evaluation, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    AIDS 20:847-53. 2006
  2. ncbi request reprint Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients
    Lisa K Naeger
    Division of Antiviral Products, Center for New Drug Evaluation, Food and Drug Administration, Silver Spring, Maryland, USA
    AIDS 21:179-85. 2007
  3. doi request reprint Running a tightrope: regulatory challenges in the development of antiretrovirals
    Lisa K Naeger
    Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States
    Antiviral Res 85:232-40. 2010
  4. pmc Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity
    Kirsten L White
    Gilead Sciences, Foster City, California 94404 ViroLogic, Inc, South San Francisco, California 94080, USA
    Antimicrob Agents Chemother 46:3437-46. 2002
  5. pmc Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations
    Kirsten L White
    Gilead Sciences, Foster City, California, 94404, USA
    Antimicrob Agents Chemother 48:992-1003. 2004
  6. pmc ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase
    Lisa K Naeger
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Antimicrob Agents Chemother 46:2179-84. 2002

Detail Information

Publications6

  1. ncbi request reprint Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients
    Lisa K Naeger
    Division of Antiviral Products, Center for New Drug Evaluation, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    AIDS 20:847-53. 2006
    ..To assess the virologic response rates of atazanavir/ritonavir and lopinavir/ritonavir based on baseline genotype and phenotype...
  2. ncbi request reprint Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients
    Lisa K Naeger
    Division of Antiviral Products, Center for New Drug Evaluation, Food and Drug Administration, Silver Spring, Maryland, USA
    AIDS 21:179-85. 2007
    ..To assess the resistance profile of tipranavir...
  3. doi request reprint Running a tightrope: regulatory challenges in the development of antiretrovirals
    Lisa K Naeger
    Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States
    Antiviral Res 85:232-40. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  4. pmc Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity
    Kirsten L White
    Gilead Sciences, Foster City, California 94404 ViroLogic, Inc, South San Francisco, California 94080, USA
    Antimicrob Agents Chemother 46:3437-46. 2002
    ....
  5. pmc Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations
    Kirsten L White
    Gilead Sciences, Foster City, California, 94404, USA
    Antimicrob Agents Chemother 48:992-1003. 2004
    ..Computer modeling suggests that the increased mobility of the beta3-beta4 loop may contribute to the high-level and broad NRTI resistance caused by the T69 insertion mutation...
  6. pmc ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase
    Lisa K Naeger
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Antimicrob Agents Chemother 46:2179-84. 2002
    ..The minimal removal of abacavir, ddC, DAPD, 3TC, ddI, and tenofovir is consistent with the minor changes in susceptibility to these drugs observed for HIV mutants with thymidine analog resistance mutations...